Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
2004-05-27
2008-09-02
Pak, Michael (Department: 1646)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
Reexamination Certificate
active
07419664
ABSTRACT:
The invention relates to methods of treating a disease or condition, wherein expression or activity of soluble CLCA1 is up-regulated, by administering inhibitors of soluble CLCA1. The invention also relates to methods of isolating soluble CLCA1 from a bodily fluid.
REFERENCES:
patent: 6716603 (2004-04-01), Holroyd et al.
patent: 1 234 878 (2002-08-01), None
patent: WO 99/44620 (1999-09-01), None
patent: WO 01/54685 (2001-08-01), None
Clarke et al., “Defective epithelial chloride transport in a gene-targeted mouse model of cystic fibrosis,”Science, 257:1125-1128 (1992).
Clarke et al., “Relationship of a non-cystic fibrosis transmembrane conductance regulator-mediated chloride conductance to organ-level disease inCftr(-l-) mice,”PNAS, 91:479-483 (1994).
Eng et al., “Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis,”Ped. Pulmonol., 21:77-83 (1996).
Gruber et al., “Genomic cloning, molecular characterization, and functional analysis of human CLCA1, the first human member of the family of Ca2+-activated CI−channel proteins,”Genomics, 54:200-214 (1998).
Hoshino et al., “Increased expression of the human Ca2+-activated CI−channel 1 (CaCC1) gene in the asthmstic airway,”Am. J. Respir. Crit. Care Med., 165:1132-1136 (2002).
Nakanishi et al., “Role of gob-5 in mucus overproduction and airway hyperresponsiveness in asthma,”PNAS, 98:5175-5180 (2001).
Welsh et al., “Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis,”Cell, 73:1251-1254 (1993).
International Search Report for PCT/US2004/016742 dated Dec. 28, 2004.
Bowman Michael
Goldman Samuel J.
Long Andrew J.
Sypek Joseph P.
Wood Clive R.
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Pak Michael
Wyeth
LandOfFree
Method of treatment using antibody to CLCA-1 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment using antibody to CLCA-1, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment using antibody to CLCA-1 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3989094